Last updated on December 2018

Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety


Brief description of study

This is a Phase IV, randomized, open-label, active-controlled, 2-arm, multicenter study. The primary objective will be assessed by the difference in the mean number of ranibizumab injections applied up to Month 11 between the 2 treatment arms. Patients will be randomized in a 1:1 ratio to 1 of the 2 treatment arms; i.e. Arm 1 ranibizumab monotherapy, Arm 2 ranibizumab with Grid&Direct short pulse laser photocoagulation combination therapy. There will be 3 periods in this study: Screening Period (visit 1), Treatment Period (visit 2 to Visit 13) and Follow-up Period (visit 14). In addition to screening and Baseline (visit 2), there will be monthly visits from Month 1 to Month 12. This study will include male and female patients (20 years old) diagnosed with visual impairment due to ME secondary to BRVO. Assuming an approximate 20% drop out rate, approximately 70 patients will need to be screened to have at least 56 patients found eligible and commencing treatment in the trial.

Clinical Study Identifier: NCT02953938

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
Nagakute-city, Japan

Novartis Pharmaceuticals

Novartis Investigative Site
Fukuoka city, Japan

Novartis Pharmaceuticals

Novartis Investigative Site
Kita-gun, Japan

Novartis Pharmaceuticals

Novartis Investigative Site
Tsu-city, Japan

Novartis Pharmaceuticals

Novartis Investigative Site
Matsumoto-city, Japan

Novartis Pharmaceuticals

Novartis Investigative Site
Mitaka-city, Japan

Novartis Pharmaceuticals

Novartis Investigative Site
Hokkaido, Japan

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.